RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Arcturus Therapeutics Holdings Stock

Arcturus Therapeutics Holdings Equity 2025

Arcturus Therapeutics Holdings Equity

240.98 M USD

Ticker

ARCT

ISIN

US03969T1097

WKN

A2PMAS

In 2025, Arcturus Therapeutics Holdings's equity was 240.98 M USD, a -13.48% increase from the 278.51 M USD equity in the previous year.

Arcturus Therapeutics Holdings Aktienanalyse

What does Arcturus Therapeutics Holdings do?

Arcturus Therapeutics is a biopharmaceutical company based in San Diego, California, founded in 2013. The company specializes in the development of RNA-based therapeutics and has developed a proprietary technology platform called "LUNAR" that enables safe and effective transport of RNA molecules into target cells. The technology, resulting from over a decade of research and development, allows for the development of drugs for a variety of diseases. Arcturus's business model focuses on forming partnerships with other pharmaceutical companies to accelerate the development of RNA-based therapeutics. The company collaborates with partners from various industries, ranging from large biotech companies to small startups, in order to promote the development of effective treatments. Arcturus also has its own pipeline of therapeutics in development. The company has formed partnerships with Janssen Pharmaceuticals, Takeda Pharmaceutical, Ultragenyx Pharmaceutical, and CureVac. Arcturus's pipeline includes a variety of therapeutics targeting different therapy areas, including oncology, critical care, and rare diseases. A key focus is on the treatment of liver diseases such as hemophilia B, alpha-1 antitrypsin deficiency, and factor VIII deficiency. Arcturus is also working on therapies for rare diseases like lysosomal storage disease and other diseases such as diabetes, kidney disease, and AIDS. One important product from Arcturus is the hepatitis B vaccine candidate, developed in partnership with Janssen Pharmaceuticals. The vaccine candidate utilizes Arcturus's LUNAR technology to generate an effective immune response against hepatitis B. Phase 2 studies of the vaccine have shown promising results, suggesting that the vaccine can play a significant role in combating hepatitis B. Another important product from Arcturus is ARO-AAT, developed for the treatment of alpha-1 antitrypsin deficiency. Deficiency of this protein can lead to liver and lung diseases, and currently there is no effective treatment method. ARO-AAT utilizes Arcturus's LUNAR technology to effectively transport RNA molecules to the affected cells. Clinical studies of ARO-AAT have been positively evaluated thus far. Arcturus also has plans to apply its RNA technology in the field of vaccine development, aiming to quickly and effectively respond to future pandemics and threats of infectious diseases. In summary, Arcturus Therapeutics is a biopharmaceutical company that has developed a proprietary RNA technology platform called LUNAR to develop safe and effective therapeutics for a variety of diseases. The company collaborates with a variety of partners to accelerate the development of RNA-based therapeutics. Arcturus has its own pipeline of therapeutics in development, including a hepatitis B vaccine candidate and ARO-AAT for the treatment of alpha-1 antitrypsin deficiency. The company also has plans to utilize its RNA technology for vaccine development to quickly and effectively respond to future infectious diseases. Arcturus Therapeutics Holdings ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Arcturus Therapeutics Holdings's Equity

Arcturus Therapeutics Holdings's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Arcturus Therapeutics Holdings's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Arcturus Therapeutics Holdings's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Arcturus Therapeutics Holdings's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Arcturus Therapeutics Holdings’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Arcturus Therapeutics Holdings stock

What is the equity of Arcturus Therapeutics Holdings this year?

Arcturus Therapeutics Holdings has equity of 240.98 M USD this year.

What was the equity of Arcturus Therapeutics Holdings compared to the previous year?

The equity of Arcturus Therapeutics Holdings has increased/decreased by -13.48% decreased compared to the previous year.

What impact does a high equity have on investors of Arcturus Therapeutics Holdings?

A high equity is advantageous for investors of Arcturus Therapeutics Holdings as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Arcturus Therapeutics Holdings?

A low equity can be a risk for investors of Arcturus Therapeutics Holdings, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Arcturus Therapeutics Holdings affect the company?

An increase in equity of Arcturus Therapeutics Holdings can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Arcturus Therapeutics Holdings affect the company?

A reduction in equity of Arcturus Therapeutics Holdings can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Arcturus Therapeutics Holdings?

Some factors that can affect the equity of Arcturus Therapeutics Holdings include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Arcturus Therapeutics Holdings so important for investors?

The equity of Arcturus Therapeutics Holdings is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Arcturus Therapeutics Holdings take to change the equity?

To change equity, Arcturus Therapeutics Holdings can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Arcturus Therapeutics Holdings pay?

Over the past 12 months, Arcturus Therapeutics Holdings paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Arcturus Therapeutics Holdings is expected to pay a dividend of 0 USD.

What is the dividend yield of Arcturus Therapeutics Holdings?

The current dividend yield of Arcturus Therapeutics Holdings is .

When does Arcturus Therapeutics Holdings pay dividends?

Arcturus Therapeutics Holdings pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Arcturus Therapeutics Holdings?

Arcturus Therapeutics Holdings paid dividends every year for the past 0 years.

What is the dividend of Arcturus Therapeutics Holdings?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Arcturus Therapeutics Holdings located?

Arcturus Therapeutics Holdings is assigned to the 'Health' sector.

Wann musste ich die Aktien von Arcturus Therapeutics Holdings kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Arcturus Therapeutics Holdings from 8/24/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/24/2025.

When did Arcturus Therapeutics Holdings pay the last dividend?

The last dividend was paid out on 8/24/2025.

What was the dividend of Arcturus Therapeutics Holdings in the year 2024?

In the year 2024, Arcturus Therapeutics Holdings distributed 0 USD as dividends.

In which currency does Arcturus Therapeutics Holdings pay out the dividend?

The dividends of Arcturus Therapeutics Holdings are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Arcturus Therapeutics Holdings

Our stock analysis for Arcturus Therapeutics Holdings Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Arcturus Therapeutics Holdings Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.